Drugs / Virus specific T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05075837 | Feb → Jul 2024 | disease related to hematopoietic stem cell transplant | Gaslini Institute | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06075927 | Nov 2023 → Jul 2025 | Epstein-Barr virus infection, cytomegalovirus infection, disease related to hematopoietic stem cell transplant | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02702427 | Aug 2016 → Apr 2019 | adenoviridae infectious disease, cytomegalovirus infection | St. Anna Children's Cancer Research | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Virus specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06075927 ↗ |
| Known as | VSTs | “Subjects will receive partial HLA-matched viral-specific T cells (VSTs) against both CMV and EBV on one of the following dose levels:” NCT06075927 ↗ |
| Modality | Cell therapy | “Biological: virus-specific T-Cells” NCT02702427 ↗ |
| Route | Intravenous | “intravenous infusion of multi-virus VSTs” NCT06075927 ↗ |